pharma.markets

pharma.markets

  • HOME
  • Imprint

Valencia Comunidad

Municipalities with the most cases of coronavirus in the Valencia Region

09/12/2021 MaP 0

Almost 20 Valencian municipalities that already exceed a 14-day cumulative incidence of more than 1,000 cases per 100,000 inhabitants. The sixth wave of the coronavirus […]

Check of covid passport in the Valencia Region’s establishments

28/11/2021 MaP 0

The covid passport will be compulsory to enter bars, restaurants and entertainment venues in the Valencian Community. The Regional Ministry of Health has decided to […]

AEMPS authorizes Phase IIb clinical trial of HIPRA Covid-19 vaccine

16/11/2021 MaP 0

The main objectives are to confirm safety and tolerability for a booster dose and to check if the booster dose prolongs the immune response to […]

37,431,385 people have received the full course of covid vaccination in Spain

12/11/2021 MaP 0

A total of 37,431,385 people in Spain have received the full course of vaccination against covid, according to the report published on Thursday by the […]

Copyright European Commission 2021

The Spanish vaccine against covid, close to commercialisation

30/10/2021 MaP 0

The Government approves funding to Hipra laboratories for its serum to advance to the final stages of clinical trials before its commercialisation. EFE The Centre […]

Spain – The vaccination schedule: when will we be vaccinated?

07/04/2021 MaP 0

The vaccination strategy will pick up pace in the coming weeks, with a gradual and steady increase towards the end of the summer. The vaccination […]

Comunidad Valencia – These are the groups to be vaccinated from 24.3.2021 onwards

24/03/2021 MaP 0

The reactivation of immunisation for the educational community will begin next Friday. The launch of the vaccination is to see, once again, the light at […]

Translation

Search

Categories

  • Age.related Degeneration
  • Alzheimer
  • Animal health
  • Asthma
  • Bioscience
  • Cancer
  • Conferences
  • Cosmetics
  • COVID-19
  • EIB
  • EU
  • FCPA Investigations
  • FDA
  • Finance
  • Food
  • HHS
  • Humanitarian Aid
  • Imprint
  • Influenza
  • Innovation
  • Mental Health
  • MS
  • News
  • Research
  • Rheumatology
  • Space Science
  • Spain
  • Sports
  • Therapy
  • Trade Fair
  • UN
  • Vaccines
  • Valencia Comunidad
  • WHO

Reports

  • Bayer expands global clinical program for darolutamide in prostate cancer
  • Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
  • Pigs as Organ Donors – New Findings on the Prevention of Retrovirus Infections
  • Nubeqa™ (darolutamide) approved for additional prostate cancer indication in China Nubeqa™ now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer
  • New four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)

Archive

  • March 2023 (15)
  • February 2023 (11)
  • January 2023 (6)
  • December 2022 (16)
  • November 2022 (11)
  • October 2022 (14)
  • September 2022 (1)
  • August 2022 (4)
  • July 2022 (3)
  • June 2022 (8)
  • May 2022 (1)
  • April 2022 (2)
  • March 2022 (5)
  • February 2022 (9)
  • January 2022 (19)
  • December 2021 (37)
  • November 2021 (17)
  • October 2021 (5)
  • August 2021 (5)
  • July 2021 (5)
  • June 2021 (1)
  • May 2021 (6)
  • April 2021 (9)
  • March 2021 (23)
  • February 2021 (22)
  • January 2021 (11)
  • December 2020 (29)
  • November 2020 (7)
  • October 2020 (6)
  • September 2020 (17)
  • August 2020 (1)
  • July 2020 (4)
  • June 2020 (99)
  • May 2020 (201)
  • April 2020 (269)
  • March 2020 (29)
  • Bayer expands global clinical program for darolutamide in prostate cancer

    23/03/2023 0
  • Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation

    21/03/2023 0
  • Pigs as Organ Donors – New Findings on the Prevention of Retrovirus Infections

    20/03/2023 0
  • Nubeqa™ (darolutamide) approved for additional prostate cancer indication in China Nubeqa™ now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer

    20/03/2023 0
  • New four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)

    20/03/2023 0
Archives
  • March 2023 (15)
  • February 2023 (11)
  • January 2023 (6)
  • December 2022 (16)
  • November 2022 (11)
  • October 2022 (14)
  • September 2022 (1)
  • August 2022 (4)
  • July 2022 (3)
  • June 2022 (8)
  • May 2022 (1)
  • April 2022 (2)
  • March 2022 (5)
  • February 2022 (9)
  • January 2022 (19)
  • December 2021 (37)
  • November 2021 (17)
  • October 2021 (5)
  • August 2021 (5)
  • July 2021 (5)
  • June 2021 (1)
  • May 2021 (6)
  • April 2021 (9)
  • March 2021 (23)
  • February 2021 (22)
  • January 2021 (11)
  • December 2020 (29)
  • November 2020 (7)
  • October 2020 (6)
  • September 2020 (17)
  • August 2020 (1)
  • July 2020 (4)
  • June 2020 (99)
  • May 2020 (201)
  • April 2020 (269)
  • March 2020 (29)
TAGS
affected africa aid bayer biontech cancer commission companies coronavirus covid-19 covid19 economy elpais.com emergency eu europe european fda food global guarantee health hygiene investment links medical merck novartis pandemic pfizer production recommendations region response roche safety scheme sector spain state statistics support test vaccine who

Copyright © 2023 | WordPress Theme by MH Themes

Cookie Consent with Real Cookie Banner